Mathai Mammen, FogPharma's next CEO
March 30, 2023 06:00 AM EDTUpdated 01:31 PM
People
Startups

Math­ai Mam­men hands in J&J's R&D keys to lead Greg Ver­dine’s Fog­Phar­ma 

Kyle LaHucik

Senior Reporter

In the ear­ly 1990s, Math­ai Mam­men was a teach­ing as­sis­tant in Greg Ver­dine’s Sci­ence B46 course at Har­vard. In June, the for­mer R&D head at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

FDA plans to ban phar­ma em­ploy­ees from serv­ing on ad­comms. The im­pact will be lim­it­ed

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times